Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1984-7-30
|
| pubmed:abstractText |
Twenty-four consecutive cases of malignant histiocytosis (MH) treated at Stanford Medical Center between 1973 and 1983 have been reviewed. Most patients presented with systemic symptoms (91%) and advanced disease (stage IV, 80%). Multiple organ involvement was common. In six cases, pathologic tissue was further characterized by frozen section immune histochemistry, using a panel of monoclonal antibodies known to react with monocytes and macrophages, as well as a variety of hematopoietic cells. One case expressed a mature monocyte/macrophage phenotype; three cases were considered null cell or primitive lesions; and two cases were identified as probable T cell lymphomas. Seven patients underwent splenectomy. Two patients died prior to any treatment. Twenty-two patients were treated with CHOP (cyclophosphamide, Adriamycin, vincristine, prednisone) +/- bleomycin (B), +/- midcycle high-dose methotrexate (HD-MTX) with leucovorin rescue. Seven patients received prophylactic intrathecal MTX. Of 22 evaluable patients, there was a 68% complete response rate (CR), a 23% partial response rate (PR), and a 9% no response rate (NR). Median duration of CR was 30+ months; median duration of PR was 2.4 months. Median survival for patients attaining a CR has not been reached v 3 months for the PR and NR groups. For all 24 patients, median survival was 2 years, with a 5-year actuarial survival of 40%. Multivariate analysis revealed that a platelet count less than 150,000 (P Cox = .005) and the dose of drug delivered (P Cox = .057) were the most important prognostic factors. Prophylactic intrathecal MTX therapy and splenectomy did not influence survival. Although MH is an aggressive disease with a poor prognosis, it is potentially curable. Systematic and aggressive treatment should further improve the outcome.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
48-53
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:6610448-Adolescent,
pubmed-meshheading:6610448-Adult,
pubmed-meshheading:6610448-Aged,
pubmed-meshheading:6610448-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6610448-Cyclophosphamide,
pubmed-meshheading:6610448-Dose-Response Relationship, Drug,
pubmed-meshheading:6610448-Doxorubicin,
pubmed-meshheading:6610448-Female,
pubmed-meshheading:6610448-Humans,
pubmed-meshheading:6610448-Leucovorin,
pubmed-meshheading:6610448-Liver Neoplasms,
pubmed-meshheading:6610448-Lymphatic Diseases,
pubmed-meshheading:6610448-Male,
pubmed-meshheading:6610448-Methotrexate,
pubmed-meshheading:6610448-Middle Aged,
pubmed-meshheading:6610448-Platelet Count,
pubmed-meshheading:6610448-Prednisone,
pubmed-meshheading:6610448-Prognosis,
pubmed-meshheading:6610448-Splenectomy,
pubmed-meshheading:6610448-Splenic Neoplasms,
pubmed-meshheading:6610448-Vincristine
|
| pubmed:year |
1984
|
| pubmed:articleTitle |
The treatment of malignant histiocytosis.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|